Compare FMC Corp (FMC) vs Medpace Holdings Inc (MEDP) Price & Performance

FMC Corporation (FMC) trades at $10.24, down 2.1% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows a bearish technical signal with key support at $10 and resistance at $11. Fundamentally, the company faces significant challenges with a net income margin of -84.83% and negative ROE of -91.47% for 2025, though valuation ratios like P/S of 0.4 and P/B of 0.8 appear attractive. Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submission for new herbicide technology.

The outlook remains cautious due to persistent profitability issues and revenue declines, with 2025 revenue dropping to $3.47B from $4.2B in 2024. While analyst consensus is mixed with a $11.60 price target suggesting modest upside, high debt levels and competitive pressures pose substantial risks. The company's focus on debt reduction through asset sales and external investments provides some stability, but turnaround execution is critical for sustained recovery.

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.